FDANews
FDAnews Device Daily Bulletin

Vyriad Signs Exclusive License Agreement for STING Technology

Aug. 8, 2016

StingInn has granted Vyriad an exclusive research license to StingInn’s technology to develop novel recombinant oncolytic viruses encoding STING.

Vyriad will use this encoding for work on its candidate oncolytic virotherapy device.

STING technology is capable of activating the cytosolic DNA-sensing pathway inside a tumor, amplifying the body’s anti-tumor immune response. — Cynthia Jessup

View today's stories